Brief Introduction

Haier Biomedical was founded to focus on design, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. Using the concept of IoT, the company has become a provider of comprehensive solutions for various biotechnological challenges. Operating globally, Haier Biomedicalhas various solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety. In 2019, the company was listed in SSE STAR Market.

As of now, Haier Biomedical and its subsidiaries have achieved a total of 361 approved patents, awarded the National Prize for Progress in Science and Technologynational in China. Our core R & D personnel have led or engaged in the drafting of 9 national and industry standards, basically covering all biomedical cryogenic storage products. Furthermore, Haier Biomedical participated in the drafting of World Health Organization (WHO) international standards, showing true leadership and development for the industry.

Haier Biomedical leads a new revolution in traditional manufacturing as well as innovative technology development. In the context of rapid development of the Internet of Things, Haier Biomedical has comprehensively promoted the integration and innovation of IoT technology and low-temperature storage technology. Combining IoT software and hardware based on network communication and radio frequency identification technology with self-developed low-temperature storage products. Haier Biomedical updated traditional storage devices to the IoT solution, which effectively meets the needs of users such as clinical blood use, vaccination, and biobank application building the leading IoT technology ecosystem.

Up to now, Haier Biomedical's IoT solutions are untilized in major national strategic projects such as CMDP, CNGB, and Chinese Human Genetic Resource Bank, and covers Beijing 301 Hospital, Shanghai Ruijin Hospital, Xi'an Jiaotong University First Affiliated Hospital, and Sichuan University West China Hospital Changsha Xiangya Hospital, First Affiliated Hospital of China Medical University, National Cardiovascular Center & Fuwai Hospital and other key top three hospitals. Moreover, Haier Biomedical's Vaccine Network is now used in a great number of inoculation sitesand building full-coverage smart city vaccine network in many areas across China. The company's solutions are now used also in international markets such as the British biological sample bank, the Swedish Karolinska Institute of Technology, Denmark, Italian public hospitals and multiple other examples from developed markets.

With superior product quality, flexible solutions and leading technology, Haier Biomedical has won the trust and recognition of comsumers widely distributed in more than 120 countries and territories. Haier Biomedical Insists on the intelligent protection of life,by empowering science and technology, and is commited to providing the best products and solutions, enhancing the advancement of world's biological technology and research.

Company Overview

Code 688139
Founded 2005-10-28
Listing 2019-10-25
Domicile Qingdao
STAR Theme Biomedicine
CSRC Sector Manufacturing
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share 1.20 0.73 0.56
R&D expenditure as a % of operating revenue 10.75% 11.99% 10.74%
Operating Revenue 1,402.03 1,012.52 841.67
Net Income 384.12 183.36 114.70

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 1,402.03 1,012.52 841.67
Operating Costs 694.11 469.51 414.53
Operating Income 427.55 215.75 135.56
Pretax Income 320.36 207.58 107.83
Income Tax 40.11 27.73 24.47
Net Income 384.12 183.36 114.70

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 2,733.97 2,561.47 1,920.66
Non-current Assets-Total 1208.63 478.53 307.10
Total Assets 3,942.60 3,040.00 2,227.75
Current Liabilities-Total 1,044.35 545.78 1,110.75
Non-current Liabilities-Total 113.73 35.30 3.25
Total Liabilities 1,158.08 581.08 1,114.00
Stockholder's Equity
Share Capital 2,192.60 2,186.89 1,025.89
Retained Profits 583.28 266.56 83.69
Minority interests 8.64 5.47 4.17
Total Owners' Equity 2,784.51 2,458.92 1,113.75

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 696.62 280.49 149.00
Net Cash Flows-Investing -135.22 373.28 -763.97
Net Cash Flows-Financing -145.16 374.54 826.23

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
青岛海尔生物医疗控股有限公司 100,591.46 31.73%
Ningbo Meishan Bonded Port Area Qijun Equity Investment Partnership(Limited Partnership) 57,163.71 18.03%
Qingdao Haichuangrui Equity Investment Fund Center(L.P.) 32,103.66 10.13%
天津海盈康企业管理合伙企业(有限合伙) 12,261.69 3.87%
天津海创盈康企业管理合伙企业(有限合伙) 11,517.74 3.63%
北京磐沣投资管理合伙企业(有限合伙)-磐沣价值私募证券投资基金 6,982.39 2.2%
China National Pharmaceutical Industry Co., Ltd. 6,589.99 2.08%
Ningbo Meishan Bonded Port Area Longhui Hecheng Investment Management Partnership(L.P.) 4,512.20 1.42%
施罗德投资管理(香港)有限公司-施罗德环球基金系列中国A股(交易所) 4,307.32 1.36%

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.